BioData Mining· 2026Q1
Development and validation of a machine learning prediction model for pediatric sepsis-associated acute kidney injury: a multicenter cohort study
- 0citations
- Q1SCImago
- 2026year
Short summary
An interpretable XGBoost machine learning model, using eight routinely available clinical parameters, accurately predicts sepsis-associated acute kidney injury (SA-AKI) in pediatric sepsis patients, achieving AUCs up to 0.899 and outperforming traditional scores.
AI-generated from the title and abstract; the full text is not read.
Key points
- An interpretable XGBoost model was developed and validated for early prediction of SA-AKI in pediatric sepsis.
- The model achieved high discrimination with AUCs up to 0.899 in the training set and 0.794-0.844 in external validation sets.
- It significantly outperformed traditional scores (pSOFA, Phoenix) in most validation cohorts.
- Top predictors identified by SHAP analysis include standard base excess, aspartate aminotransferase, and potassium.
- The model demonstrated clinical utility, providing net benefit within clinically relevant thresholds.
AI-generated from the title and abstract; the full text is not read.
Abstract
Sepsis-associated acute kidney injury (SA-AKI) significantly increases mortality in pediatric sepsis patients. However, early warning tools for pediatric cases remain scarce. This study aimed to develop and validate an interpretable machine learning model for the early prediction of SA-AKI in pediatric sepsis. This multicenter retrospective cohort study analyzed data from pediatric sepsis patients admitted to pediatric intensive care units (PICUs) at five Chinese centers. Patients were stratified into training, internal temporal validation, and four external validation cohorts. A rigorous feature selection process identified the most predictive variables from 41 routinely available clinical parameters within 24 hours of admission. Ten machine learning algorithms were trained and optimized, with the model achieving the highest area under the curve (AUC) selected as the final model. Model interpretability was achieved using SHapley Additive exPlanations (SHAP). A total of 3,437 pediatric sepsis patients were included, with an overall SA-AKI incidence of 25.7%. The XGBoost model was selected as the optimal algorithm, demonstrating robust discrimination across all cohorts, with AUCs of 0.899 (95% CI: 0.88–0.91) in the training set, 0.854 (95% CI: 0.81–0.89) in the internal temporal validation set, and ranging from 0.794 to 0.844 across four external validation sets. The model significantly outperformed traditional clinical scores (pSOFA and Phoenix) in most cohorts (all p < 0.05), although its discrimination was comparable to that of pSOFA in the PIC validation cohort; calibration was acceptable in most cohorts but poorer in the PIC cohort, where the model under-predicted AKI risk. Decision curve analysis confirmed net clinical benefit within the clinically plausible threshold range of 5%–50%, and over the treat-all strategy at thresholds above approximately 10%. SHAP analysis revealed standard base excess (SBE), aspartate aminotransferase (AST), and potassium as the top predictors of SA-AKI, with dependence plots elucidating their nonlinear relationships with SA-AKI risk. This study developed and validated an explainable XGBoost model for early pediatric SA-AKI prediction. Utilizing eight routinely available parameters, the model demonstrated robust multicenter discrimination, superior or comparable performance to traditional scores, and potential clinical utility. By enabling timely, interpretable risk stratification for high-risk children, this tool addresses a critical gap in pediatric SA-AKI prediction and holds promise for guiding early kidney-protective strategies. Given the retrospective design and the all-China validation context, prospective implementation and impact studies are warranted before clinical deployment.
The authors' abstract, as published at the source. BioData Mining, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Nephrology
NephrologyMedicine